Decreased exhaled nitric oxide in mild persistent asthma patients treated with a leukotriene receptor antagonist, pranlukast.
Exhaled nitric oxide (NO) level decreases after corticosteroid treatment in asthmatics, but the effect of a leukotriene receptor antagonist, pranlukast, on exhaled NO has not been elucidated. Pranlukast treatment in mild persistent asthmatics for 4 weeks decreased the exhaled NO level, which did not differ from the levels in healthy subjects.
Kobayashi
H
H
Department of Medicine, School of Medicine, Kitasato University, Sagamihara, 228-8555, Japan. hiro@kitasato-u.ac.jp.
Takahashi
Y
Y
Mitsufuji
H
H
Hataishi
R
R
Cui
T
T
Tanaka
N
N
Kawakami
T
T
Tomita
T
T
D000328:Adult; D018927:Anti-Asthmatic Agents / Q000008:administration & dosage*; D001249:Asthma / Q000188:drug therapy* / Q000378:metabolism*; D002867:Chromones / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D020024:Leukotriene Antagonists / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D009569:Nitric Oxide / Q000378:metabolism*; D018077:Receptors, Leukotriene / Q000378:metabolism
D018927:Anti-Asthmatic Agents; D002867:Chromones; D020024:Leukotriene Antagonists; D018077:Receptors, Leukotriene; D009569:Nitric Oxide; C047681:pranlukast